| 孙晓楠,吕萌,程国亭.药物性肝损伤139例回顾性分析.[J].中南医学科学杂志.,2022,(3):391-394. |
| 药物性肝损伤139例回顾性分析 |
| Retrospective analysis of 139 cases of drug-induced liver injury |
| 投稿时间：2021-06-13 修订日期：2022-01-20 |
| DOI：10.15972/j.cnki.43-1509/r.2022.03.020 |
| 中文关键词: 药物 肝损伤 RUCAM量表 病因 |
| 英文关键词:drug liver injury RUCAM scale cause of disease constitution |
| 基金项目:河南省医学科技攻关计划联合共建项目(LHGJ20190975) 作者简介:孙晓楠,硕士,主管药师,研究方向为抗感染临床药学及合理用药,E-mail为treeflowera@163.com。 |
|
| 摘要点击次数: 461 |
| 全文下载次数: 578 |
| 中文摘要: |
| 目的探讨某医院药物性肝损伤(DILI)患者的临床特点、病因构成及应对策略。方法采用Roussel Uelaf因果关系(RUCAM)量表选择某医院DILI患者139例,收集其临床资料,分析其临床特点和用药情况。结果RUCAM量表共筛选出139例DILI,患者45~59年龄段占比最高(38.85%),61.15%患者有临床表现,其中以纳差最多见。药物性肝损伤以肝细胞损伤型最多(87.05%)。肝细胞损伤型治疗有效率高于胆汁淤积型和混合型。共涉及88种可疑药物,排名前3位依次为抗结核药物、抗肿瘤药物和中药。51.08%患者联用2种以上可疑药物。结论DILI隐蔽性强,可由多种药物引发,应提高对DILI的认识和预防,从而降低DILI的发生。 |
| 英文摘要: |
| To explore clinical characteristics, cause of disease constitution and coping strategies of patients with drug-induced liver injury (DILI) in a hospital. MethodsThe Roussel Uelaf causality relationship (RUCAM) scale was used to select 139 patients with DILI in a hospital. The clinical data of patients were collected, and the clinical characteristics and drug use were analyzed. ResultsA total of 139 patients of DILI were screened by the RUCAM scale. 45~59 age group accounted for the highest proportion (38.85%) and 61.15% of patients had clinical manifestations, among which anorexia (35.97%) was the most common. The main clinical type of the drug-induced liver injury was the hepatocyte injury type (87.05%). The treatment efficiency of hepatocyte type was higher than the cholestasis type and the mixed type. A total of 88 kinds of suspicious drugs were involved in this study, in which the top three were anti-tuberculosis drugs, anti-tumor drugs and traditional Chinese medicine. 51.08%of patients were combined with two or more suspicious drugs. ConclusionsDILI is highly concealed and could be triggered by a variety of drugs. The awareness and prevention of DILI should be improved to reduce the occurrence of DILI. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|